Search Results - "PRONK, L"

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours by ATTARD, G, KITZEN, J, BLAGDEN, S. P, FONG, P. C, PRONK, L. C, ZHI, J, ZUGMAIER, G, VERWEIJ, J, DE BONO, J. S, DE JONGE, M

“…Pertuzumab represents the first in a new class of targeted therapeutics known as HER dimerisation inhibitors. We conducted a phase Ib study to determine the…”
Get full text

The phospholipid composition and cholesterol content of platelet‐derived microparticles: a comparison with platelet membrane fractions by BIRÓ, É., AKKERMAN, J. W. N., HOEK, F. J., GORTER, G., PRONK, L. M., STURK, A., NIEUWLAND, R.

“…Background: The processes that govern the distribution of molecules between platelets and the microparticles (MP) they release are unknown. Certain proteins…”
Get full text

Phase II study comparing pembrolizumab (PEM) with intermittent/short‐term dual MAPK pathway inhibition plus PEM in patients harboring the BRAFV600 mutation (IMPemBra) by Rozeman, E.A., Sikorska, K., Grijpink-Ongering, L., Heeres, B.C., van de Wiel, B.A., Sari, A., Mallo, H., Adriaansz, S., Uyterlinde, W., Lijnsvelt, J., Pronk, L.M., Haanen, J.B.A.G., de Groot, J.W.B., Wilgenhof, S., Vollenbergh, M.A., van Thienen, J.V., Blank, C.U.

Get full text

Downsizing of locally advanced stage III (bulky) BRAF V600E/K melanoma with combination targeted therapy to achieve R0 resection by Haanen, J, Blank, C, Van Thienen, H, Mallo, H, Adriaansz, S, Ter Meulen, S, Madu, M, Pronk, L, Van der Hiel, B, Van de Wiel, B, Peeper, D, Van Akkooi, A

Get full text

Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma by Rohaan, M.W., Borch, T.H., van den Berg, J.H., Geukes Foppen, M.H., Donia, M., Met, Ö, Nuijen, B., van Zon, M., Bakker, E.A.M., de Boer, R., Pronk, L.M., Wilgenhof, S., Blank, C.U., van Thienen, J.V., van Akkooi, A.C.J., Svane, I.-M., Haanen, J.B.A.G.

Get full text

A phase lb study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours by Attard, G, Kitzen, J, Blagden, S P, Fong, P C, Pronk, L C, Zhi, J, Zugmaier, G, Verweij, J, de Bono, JS, de Jonge, M

“…Pertuzumab represents the first in a new class of targeted therapeutics known as HER dimerisation inhibitors. We conducted a phase lb study to determine the…”
Get full text

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours by PRONK, L. C, VASEY, P, SPARREBOOM, A, REIGNER, B, PLANTING, A. S. T, GORDON, R. J, OSTERWALDER, B, VERWEIJ, J, TWELVES, C

“…Capecitabine and docetaxel are both active against a variety of solid tumours, while their toxicity profiles only partly overlap. This phase I study was…”
Get full text

Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy by VAN DEN BENT, M. J, KROS, J. M, PUNT, C. J. A, BOOGERD, W, HEIMANS, J. J, PRONK, L. C, VAN GROENINGEN, C. J, KROUWER, H. G. J, TAPHOORN, M. J. B, ZONNENBERG, B. A, TIJSSEN, C. C, TWIJNSTRA, A

Get full text

Intervening sequences in rrl genes and fragmentation of 23S rRNA in genera of the family Enterobacteriaceae by Pronk, L M, Sanderson, K E

“…Intervening sequences (IVSs) in the rrl genes for 23S rRNA are transcribed but later removed by RNase III without religation during RNA processing, leading to…”
Get full text

Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors by Pronk, L C, Schellens, J H, Planting, A S, van den Bent, M J, Hilkens, P H, van der Burg, M E, de Boer-Dennert, M, Ma, J, Blanc, C, Harteveld, M, Bruno, R, Stoter, G, Verweij, J

“…This phase I study was performed to assess the feasibility of the combination of docetaxel and cisplatin and to determine the maximum-tolerated dose (MTD) and…”
Get more information

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin by HILKENS, P. H. E, PRONK, L. C, VERWEIJ, J, VECHT, C. J, VAN PUTTEN, W. L. J, VAN DEN BENT, M. J

“…Docetaxel, a new semisynthetic taxoid that has demonstrated promising activity as an antineoplastic agent, was administered in combination with cisplatin to 63…”
Get full text

Docetaxel (Taxotere): Single agent activity, development of combination treatment and reducing side-effects by Pronk, Linda C., Stoter, Gerrit, Verweij, Jaap

“…Docetaxel is a new semi-synthetic taxoid, which acts as an antimicrotubule agent and is now clinically available. Clinical studies of docetaxel as a single…”
Get full text

Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer by Aranda, E., Carrato, A., Cervantes, A., Sastre, J., Gómez, M. A., Abad, A., Masutti, B., Ribera, F., Marcuello, E., Pronk, L., Balcells, M., Díaz-Rubio, E.

“…Background: We conducted a phase I/II study of weekly irinotecan [30 min intravenous (i.v.) infusion] combined with 5-fluorouracil (5-FU 3 g/m2 weekly 48 h…”
Get full text

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours by PRONK, L. C, SCHRIJVERS, D, SCHELLENS, J. H. M, DE BRUIJN, E. A, PLANTING, A. S. T, LOCCI-TONELLI, D, GROULT, V, VERWEIJ, J, VAN OOSTEROM, A. T

“…Docetaxel and ifosfamide have shown significant activity against a variety of solid tumours. This prompted a phase I trial on the combination of these drugs…”
Get full text

Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial by STOUTHARD, J. M. L, GOEY, H, DE VRIES, E. G. E, DE MULDER, P. H, GROENEWEGEN, A, PRONK, L, STOTER, G, SAUERWEIN, H. P, BAKKER, P. J. M, VEENHOF, C. H. N

“…A phase II trial investigating the anti-tumour effects of recombinant human interleukin 6 (rhIL-6) in patients with metastatic renal cell cancer was carried…”
Get full text

JS07.4.A A PHASE 0/IA STUDY OF BRIGIMADLIN CONCENTRATION IN BRAIN TISSUE AND A DOSE ESCALATION STUDY OF BRIGIMADLIN PLUS RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA by Sarkaria, J N, Mrugala, M M, Jaeckle, K A, Burns, T C, Vaubel, R A, Parney, I F, Chaichana, K L, Clement, P M, Martínez-García, M, Sepúlveda Sanchez, J M, Omuro, A, Pronk, L, Ross, H, Teufel, M, Hesse, R, Grempler, R, Galanis, E

“…Abstract BACKGROUND Mouse double minute 2 (MDM2) inhibits the tumor suppressor protein 53 (p53). Brigimadlin, a potent oral MDM2-p53 antagonist, restores…”
Get full text

Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel by Pronk, L C, Hilkens, P H, van den Bent, M J, van Putten, W L, Stoter, G, Verweij, J

“…Docetaxel is a new antimicrotubule agent that induces a predominantly sensory neuropathy that is mild in most patients. This prospective study was performed to…”
Get more information

The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study by PRONK, L. C, VAN PUTTEN, W. L. J, VAN BEURDEN, V, DE BOER-DENNERT, M, STOTER, G, VERWEIJ, J

“…Fluid retention, which includes peripheral edema, ascites, pleural or pericardial effusion, or a combination of these that is sometimes associated with…”
Get full text

Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial) by Rozeman, E.A., Deken, M.A., Gadiot, J., Geukes Foppen, M.H., Pronk, L., Thienen, J.V., Haanen, J.B., Blank, C.U.

Get full text

Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial) by Rozeman, E.A., Deken, M.A., Gadiot, J., Geukes Foppen, M.H., Pronk, L., Thienen, J.V., Haanen, J.B., Blank, C.U.

Get full text